Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Oncol. Aug 24, 2019; 10(8): 283-292
Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283
Table 4 Comparison of studies analyzing the effect of castrate testosterone levels in intermediate and high risk prostate cancer patients receiving androgen deprivation treatment and definitive radiotherapy
Bryant et al[15]Nabid et al[16]Current study
Patient number764796173
Hormone treatmentADT+/- AAADT+/- AAADT+AA
Follow up (yr)5.279.1510.4
RT doseUnknownUnknown73.4-76 Gy
RT techniqueUnknownUnknown3DCRT-IMRT
Biochemical relapse rate
< 20 ng/dL18.3% (10 yr)20.8%17% (10 year)
20-49 ng/dL28.1% (10 yr)24.9%35% (10 year)